globaltaxnews.ey.comSign up for tax alert emailsForwardPrintDownload |
13 January 2021 How the pandemic has changed the rules for life sciences deals COVID-19 became an unexpected M&A hurdle, as life sciences deal values failed to reach the annual new normal of US$200 billion. An EY article provides details. Document ID: 2021-5036 |